0.75Open0.70Pre Close4 Volume183 Open Interest3.50Strike Price268.00Turnover69.52%IV1.24%PremiumDec 20, 2024Expiry Date0.54Intrinsic Value100Multiplier18DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.8477Delta0.3804Gamma6.73Leverage Ratio-0.0045Theta0.0014Rho5.71Eff Leverage0.0021Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet